Systematic review and meta-analysis of Statins-Fibrates therapy in diabetic dyslipidemia patients

Figure 1 Flow diagram of study screening process. IFG: Impaired fasting glucose; IGT: Impaired glucose tolerance.

Figure 2 Summary of results of meta-analysis on the lipid modifying function between coadministration of statins and fibrates and statins monotherapy. A: Comparison of plasma TC concentration between coadministration and statins monotherapy; B: Comparison of plasma TG concentration between coadministration and statins monotherapy; C: Comparison of plasma HDL-C concentration between coadministration and statins monotherapy; D: Comparison of plasma LDL-C concentration between coadministration and statins monotherapy. LDL-C: Low density lipoprotein cholesterol; HDL-C: High density lipoprotein cholesterol; TG: Triglyceride.

Figure 3 Summary of results of meta-analysis on the lipid modifying function between coadministration of statins and fibrates and fibrates monotherapy. A: Comparison of plasma TC concentration between coadministration and fibrates monotherapy; B: Comparison of plasma TG concentration between coadministration and fibrates monotherapy; C: Comparison of plasma HDL-C concentration between coadministration and fibrates monotherapy; D: Comparison of plasma LDL-C concentration between coadministration and fibrates monotherapy. LDL-C: Low density lipoprotein cholesterol; HDL-C: High density lipoprotein cholesterol; TG: Triglyceride.

Figure 4 Summary of results of meta-analysis on cardiovascular diseases. A: Primary clinical endpoints events; B: Secondary clinical endpoints events.

Figure 5 Summary of results of meta-analysis on adverse events. A: Hepatic-related adverse events; B: Muscular-related adverse events.